Peregrine Capital Management LLC Ironwood Pharmaceuticals Inc Transaction History

Peregrine Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$9.04 - $11.86 $9.26 Million - $12.1 Million	-1,023,882 Closed	0 $0
Q4 2020 Jan 19, 2021	SELL	$9.05 - $12.2 $842,998 - $1.14 Million	-93,149 Reduced 8.34%	1,023,882 $11.7 Million
Q3 2020 Oct 20, 2020	SELL	$8.99 - $10.74 $955,160 - $1.14 Million	-106,247 Reduced 8.69%	1,117,031 $10 Million
Q2 2020 Jul 30, 2020	SELL	$9.14 - $11.97 $375,096 - $491,236	-41,039 Reduced 3.25%	1,223,278 $12.6 Million
Q1 2020 Apr 17, 2020	BUY	$8.58 - $14.01 $37,494 - $61,223	4,370 Added 0.35%	1,264,317 $12.8 Million
Q4 2019 Jan 16, 2020	SELL	$8.22 - $14.0 $121,187 - $206,402	-14,743 Reduced 1.16%	1,259,947 $16.8 Million
Q3 2019 Oct 16, 2019	BUY	$8.59 - $10.96 $359,989 - $459,311	41,908 Added 3.4%	1,274,690 $10.9 Million
Q2 2019 Jul 18, 2019	BUY	$9.8 - $12.89 $12.1 Million - $15.9 Million	1,232,782 New	1,232,782 $0

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $645M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.